Clinical Trials
Phase 3 Study of YERVOY Metastatic Melanoma Meets Primary Endpoint of Overall Survival
Bristol-Myers Squibb Company announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY™ (ipilimumab) prolonged the lives of patients with metastatic melanoma. The data were published today in the New England Journal of Medicine and...
Clinical Trials
Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer
Roche announced results from OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer. Women who received...
Clinical Trials
Adaptimmune announces Opening of Phase I/II Clinical Trial in Multiple Myeloma
Adaptimmune announced that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy. ...
Clinical Trials
First ever study to apply therapeutic approach of global immune reconstitution to treatment of cancer patients
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard (Lyon), the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies...
Clinical Trials
FDA approves linagliptin tablets for the treatment of type 2 diabetes
Boehringer Ingelheim and Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes....
Clinical Trials
Gilead and MicroDose Therapeutx Announce License and Collaboration Agreement to Develop MDT-637
Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. today announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose's inhalable small molecule antiviral fusion inhibitor for the...
Clinical Trials
Biogen Idec Receives Positive Opinion from the CHMP and Authorisation from Health Canada on AVONEX PEN
Biogen Idec announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of AVONEX(R) PEN(TM) for patients with relapsing multiple sclerosis (MS) and patients with a...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.